Molecular Medicine

, Volume 19, Issue 1, pp 367–376 | Cite as

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

  • Petros D. Grivas
  • Kathleen C. Day
  • Andreas Karatsinides
  • Alyssa Paul
  • Nazia Shakir
  • Iya Owainati
  • Monica Liebert
  • Lakshmi P. Kunju
  • Dafydd Thomas
  • Maha Hussain
  • Mark L. Day
Research Article


Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domains of epidermal growth factor receptor (EGFR), HER2 and HER4 that has exhibited vigorous efficacy against other solid tumors. We evaluated the antitumor activity of dacomitinib in human bladder cancer cell lines expressing varying levels of HER family receptors. These cell lines also were established as bladder cancer xenografts in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice to assess dacomitinib activity in vivo. Significant cytotoxic and cytostatic effects were noted in cells expressing elevated levels of the dacomitinib target receptors with apoptosis and cell cycle arrest being the predominant mechanisms of antitumor activity Cells expressing lower levels of HER receptors were much less sensitive to dacomitinib. Interestingly, dacomitinib was more active than either trastuzumab or cetuximab in vitro, and exhibited increased growth inhibition of bladder tumor xenografts compared with lapatinib. Pharmacodynamic effects of dacomitinib included decreased E-cadherin (E-cad) expression, reduction of EGFR and extracellular signal-regulated kinase (ERK) phosphorylation and reduced mitotic count. Dacomitinib also inhibited tumor growth in a chemotherapy-resistant xenograft and, when combined with chemotherapy in a sensitive xenograft, exhibited superior antitumor effects compared with individual treatments. Evaluation in xenograft-bearing mice revealed that this combination was broadly feasible and well tolerated. In conclusion, dacomitinib exhibited pronounced activity both as a single agent and when combined with chemotherapy in human bladder cancer models. Further investigation of dacomitinib in the preclinical and clinical trial settings is being pursued.



The authors would like to thank Pfizer Inc, Alan Kraker, Greg Shelley, Stephanie Daignault, Anosike Nwokoye, Steven Wilson, Evan Keller and David C Smith.

Supplementary material

10020_2013_1901367_MOESM1_ESM.pdf (85 kb)
Supplementary material, approximately 85.2 KB.


  1. 1.
    Grivas PD, Day M, Hussain M. (2011) Urothelial carcinomas: a focus on human epidermal receptors signaling. Am. J. Transl. Res. 3:362–73.Google Scholar
  2. 2.
    Bazley LA, Gullick WJ. (2005) The epidermal growth factor receptor family. Endocr. Relat. Cancer. 12 Suppl 1:S17–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Klapper LN, Kirschbaum MH, Sela M, Yarden Y. (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77:25–79.CrossRefPubMedGoogle Scholar
  4. 4.
    Peles E, et al. (1993) Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12:961–71.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Citri A, Skaria KB, Yarden Y. (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell. Res. 284:54–65.CrossRefPubMedGoogle Scholar
  6. 6.
    King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. (1988) Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J. 7:1647–51.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Monsey J, Shen W, Schlesinger P, Bose R. (2010) Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J. Biol. Chem. 285:7035–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Nicholson RI, Gee JMW, Harper ME. (2001) EGFR and cancer prognosis. Eur. J. Cancer. 37:S9–S15.CrossRefPubMedGoogle Scholar
  9. 9.
    Takeuchi A, et al. (2012) Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int. J. Oncol. 40:1691–6.PubMedGoogle Scholar
  10. 10.
    Chow NH, et al. (1997) Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17:1293–6.PubMedGoogle Scholar
  11. 11.
    Kramer C, et al. (2007) Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 109:2016–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Kolla SB, et al. (2008) Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol. 40:321–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Tsai YS, Tzai TS, Chow NH. (2007) Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol. Int. 79:210–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Skagias L, et al. (2009) Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ research. J. BUON. 14:457–62.Google Scholar
  15. 15.
    Bolenz C, et al. (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 106:1216–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Alexa A, et al. (2010) Clinical significance of Her2/neu overexpression in urothelial carcinomas. Rom. J. Morphol Embryol 51:277–82.Google Scholar
  17. 17.
    Bellmunt J, Hussain M, Dinney CP. (2003) Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit. Rev. Oncol. Hematol. 46 Suppl: S85–104.CrossRefPubMedGoogle Scholar
  18. 18.
    Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. (2005) Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br. J. Cancer. 92:125–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Munk M, Memon AA, Nexo E, Sorensen BS. (2007) Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. BJU Int. 99:196–201.CrossRefPubMedGoogle Scholar
  20. 20.
    Ross J, et al. (2013) Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. Jul 26 [Epub ahead of print].Google Scholar
  21. 21.
    Iyer G, et al. (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31:3133–40.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. (2007) Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens—evidence of schedule-dependent synergy. Urology. 69:390–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Perrotte P, et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5:257–65.PubMedGoogle Scholar
  24. 24.
    Inoue K, et al. (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6:4874–84.PubMedGoogle Scholar
  25. 25.
    Grivas P, et al. (2012) Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). J. Clin. Oncol. 30 (15 Suppl). Abstact No. 4506.Google Scholar
  26. 26.
    Wülfing C, et al. (2009) A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 115:2881–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Jänne PA, et al. (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin. Cancer Res. 17:1131–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Engelman JA, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67:11924–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Ramalingam SS, et al. (2012) Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 30:3337–44.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Nam HJ, et al. (2012) The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest. New Drugs. 30:2148–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Nam HJ, et al. (2012) Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther. 11:439–51.CrossRefGoogle Scholar
  32. 32.
    Kalous O, et al. (2012). Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol. Cancer Ther. 11:1978–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Sabichi A, et al. (2006) Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 175:1133–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Hussain MH, et al. (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25:2218–24.CrossRefPubMedGoogle Scholar
  35. 35.
    Sergina NV, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinaseinactive HER3. Nature. 445:437–41.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 27:3944–56.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Tsai YS, Cheng HL, Tzai TS, Chow NH. (2012) Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta-analysis. Adv. Urol. 2012:181964.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Quesnelle KM, Grandis JR. (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin. Cancer Res. 17:5935–44.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Oh DY, et al. (2012) A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J. Clin. Oncol. 30 (suppl 4; abstr 54).Google Scholar
  40. 40.
    Black PC, et al. (2008) Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin. Cancer Res. 14:1478–86.CrossRefPubMedGoogle Scholar
  41. 41.
    Chiong E, et al. (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin. Cancer Res. 17:2863–73.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Ithimakin S, et al. (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 73:1635–46.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Roberts JT, et al. (2006) Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann. Oncol. 17 Suppl 5:v118–22.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2013

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Petros D. Grivas
    • 1
    • 4
    • 5
  • Kathleen C. Day
    • 3
    • 4
    • 5
  • Andreas Karatsinides
    • 3
  • Alyssa Paul
    • 3
  • Nazia Shakir
    • 3
  • Iya Owainati
    • 3
  • Monica Liebert
    • 3
  • Lakshmi P. Kunju
    • 2
  • Dafydd Thomas
    • 2
  • Maha Hussain
    • 1
    • 3
    • 5
  • Mark L. Day
    • 3
    • 4
    • 5
    • 6
  1. 1.Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of PathologyUniversity of MichiganAnn ArborUSA
  3. 3.Department of UrologyUniversity of MichiganAnn ArborUSA
  4. 4.Translational Oncology ProgramUniversity of MichiganAnn ArborUSA
  5. 5.University of Michigan Comprehensive Cancer Center, University of MichiganAnn ArborUSA
  6. 6.Ann ArborUSA

Personalised recommendations